L. reuteri DSM 17938 (Aldermis®)
Atopic Dermatitis in Infants
Key Facts
About BioGaia
BioGaia AB is a publicly traded, revenue-generating leader in the microbiome space, with a 30+ year legacy built on rigorous science and its proprietary *Lactobacillus reuteri* strains. Its mission is to support health from infancy to adulthood through its 'EvidenceBiotics™' portfolio, sold in over 100 countries via consumer and professional healthcare channels. The company's strategy centers on expanding its product lines, reinforcing its scientific brand, and leveraging its established global distribution to drive growth in the expanding probiotic market.
View full company profile